San Francisco, California, May 22, 2018: The global market for vulvodynia has been expanding on account of the efforts of the medical fraternity to improve women’s health. A report by TMR research brings to the fore several factors that contribute to the growth of the global market for vulvodynia. The report is titled “Vulvodynia Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”. Vulvodynia is a medical condition in women that causes severe pain and discomfort at the opening of the vulva. The condition may even hinder the normal functioning of life by making it difficult to walk, exercise, or have sex. Several factors including excessive strenuous activity, insertion of tampons, wearing tight undergarments, and prolonged sitting are believed the cause vulvodynia. The global market for vulvodynia is expected to expand at an astral rate due to the rising awareness about the medical condition across the globe.
The healthcare industry has been steadfast in launching awareness campaigns to inform and educate women about vulvodynia, This has played a pivotal role in amplifying the growth of the global market for vulvodynia treatment. Moreover, better diagnostic services coupled with safer medical procedures have also escalated demand within the global market for vulvodynia. Despite the availability of treatment options for vulvodynia, the disease is often diagnosed in the later stages. This deprives a large pool of patients from getting proper treatment, and restrains the growth of the global market.
Get Sample Copy of this Report @
The prominence of medical research across North America has given supremacy the regional market over all other regional segment.
Some of the leading players in the global market for vulvodynia treatment are Sanofi Aventis, Noven Pharmaceuticals, Inc., and Pfizer Inc.